Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores
BOULDER, CO / ACCESSWIRE / May 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its MicrocynAH® animal health care products in the Menards® chain of home improvement stores in the United States.
Menards is a family-owned company started in 1958 and headquartered in Eau Claire, Wisconsin. It has more than 300 home improvement stores located in Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, West Virginia, Wisconsin, and Wyoming. Sonoma’s MicrocynAH products are distributed in the U.S. and Canada through its partner, Compana Pet Brands.
MicrocynAH products available through Menards stores and online include: Wound & Skin Care Spray, Wound & Skin Care Hydrogel, Eye & Ear Wash, Anti-Itch Gel Spray with Dimethicone and Hot Spot Gel Spray with Dimethicone.
“We are excited to see the increased availability of our animal health care products into Menards stores,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. “Our Microcyn technology is safe and effective for any species, including dogs, cats, birds, reptiles and other animals, and with this expansion more pet owners will be able to find relief for their pets’ common ailments.”
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
About Compana Pet Brands
With roots dating back to 1842, Compana Pet Brands is a global leader in pet care and nutrition dedicated to enriching the lives of pets and their families. Based in St. Louis and employing approximately 700 passionate pet lovers around the world, the company manufactures and markets more than 20 household brands in dog and cat, backyard chicken, equine, small animal and indoor bird categories. Compana believes pets are an important part of the family and its broad portfolio of brands focuses on care and wellness solutions to improve the quality of life for pets of all shapes and sizes throughout their lifespans. For more information, visit companapetbrands.com or follow Compana on LinkedIn.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop,” “anticipate,” “expect” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Microcyn® and MicrocynAH® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
